Stay updated with breaking news from Pediatric Immunotherapy Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Augusta (Georgia), April 25: Children with recurrent brain tumours tolerated the first in-human trial of a novel immunotherapy well, and many were able to experience unexpected months of a more normal life, according to researchers. Immunotherapy disables a natural enzyme that tumours hijack for their defence.
The first in-human-study of a new immunotherapy that blocks a natural enzyme tumors commandeer for their protection was well tolerated by children with relapsed brain tumors and enabled many to have unexpected months of a more normal life, researchers say.
The first in-human-study of a new immunotherapy that blocks a natural enzyme tumors commandeer for their protection was well tolerated by children with relapsed brain tumors and enabled many to have unexpected months of a more normal life, researchers say.
Children with recurrent brain tumours tolerated the first in-human trial of a novel immunotherapy well, and many were able to experience unexpected months of a more normal life, according to researchers
The conversations between our bone and muscle change as we age, and both are the weaker for it, Medical College of Georgia scientists say.